Payment overview · 2025
General Payments
$267.78
14 reported records · 7 companies
Healthcare provider profile · identity verified
Melanie Marshall, MD
Allopathic & Osteopathic Physicians|Family Medicine · OKLAHOMA CITY, OK · NPI 1649590837
Verified facts
What the public records show
CMS Open Payments records show Melanie Marshall, MD received $267.78 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.04 | 36.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.16 | 22.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.40 | 12.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.44 | 11.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.32 | 6.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.62 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.80 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.78 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $97.04 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.04 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.16 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.16 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.44 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 61 |
| Omeprazole | Omeprazole | 190 | 56 |
| Losartan Potassium | Losartan Potassium | 178 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 40 |
| Lisinopril | Lisinopril | 142 | 43 |
| Gabapentin | Gabapentin | 118 | 38 |
| Montelukast Sodium | Montelukast Sodium | 107 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 37 |
| Spironolactone | Spironolactone | 91 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 23 |
| Mounjaro | Tirzepatide | 74 | 13 |
| Jardiance | Empagliflozin | 71 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 22 |
| Sertraline Hcl | Sertraline Hcl | 68 | 21 |
| Potassium Chloride | Potassium Chloride | 65 | 21 |
| Alendronate Sodium | Alendronate Sodium | 62 | 19 |
| Simvastatin | Simvastatin | 62 | 18 |
| Alprazolam | Alprazolam | 58 | 15 |
| Furosemide | Furosemide | 58 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 15 |
| Meloxicam | Meloxicam | 53 | 17 |
| Ozempic | Semaglutide | 49 | 13 |
| Eliquis | Apixaban | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 12 |
| Metformin Hcl | Metformin Hcl | 44 | 16 |
| Azithromycin | Azithromycin | 41 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | 14 |
| Famotidine | Famotidine | 35 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Atenolol | Atenolol | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | 12 |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.78 · 14 records | ABBVIE INC. | ABRYSVO, AREXVY, BEXSERO, CAPLYTA, COMIRNATY, FREESTYLE LIBRE 3, Ozempic, PEDIARIX, PENBRAYA, PENMENVY, PREVNAR 20, QULIPTA, SHINGRIX, TRUMENBA, UBRELVY, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error